Below are the most recent publications written about "Esophageal Neoplasms" by people in Profiles.
-
Matsui K, Miyawaki Y, Suzuki Y, Furube T, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Dis Esophagus. 2026 Mar 02; 39(2).
-
Deng Z, Pu L, Deng K, Liu W, Zhang J, Zhang L, Meng Q, Zhou W, Jin H, Xu D, Qi S, Wu Z, Ma Y, Liu X, Yao X, Ke B, Kerr DJ, Yang L, Yang J, Jiang H. Targeting TFAP2? condensation suppresses the development of esophageal squamous cell carcinoma. Cell. 2026 Feb 05; 189(3):887-905.e25.
-
Yoshizawa M, Miyawaki Y, Sato H, Kawasaki T, Furube T, Matsui K, Suzuki Y, Toriumi T, Kishimoto Y, Ebara G, Hirano Y, Okamoto K, Sakuramoto S. Esophageal Lymphoepithelioma-like Carcinoma With a Remarkable Response to DCF Chemotherapy: A Case Report. Anticancer Res. 2025 Oct; 45(10):4643-4652.
-
Matsui K, Miyawaki Y, Kobayashi R, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel?+?cisplatin?+?5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. Int J Clin Oncol. 2025 Oct; 30(10):1992-2002.
-
Cruz-Correa M, Xu RH, Moehler M, Oh DY, Kato K, Spigel D, Arkenau HT, Tabernero J, Zimina AV, Bai Y, Shi J, Lee KW, Hirano H, Wyrwicz L, Cid RP, Xu H, Sheng T, Barnes G. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma: patient-reported outcomes in the RATIONALE-305 study. Curr Med Res Opin. 2025 Jun; 41(6):1007-1016.
-
Nemati S, Islami F, Kamangar F, Poustchi H, Roshandel G, Shakeri R, Domingues A, Khoshnia M, Gharavi A, Brennan P, Abnet CC, Dawsey SM, Boffetta P, Malekzadeh R, Sheikh M. Improvement of esophageal cancer survival in Northeast Iran: A two-decade journey in a high-risk, low- resource region. PLoS One. 2024; 19(9):e0310842.
-
Inoue-Choi M, Freedman ND, Etemadi A, Hashemian M, Brennan P, Roshandel G, Poustchi H, Boffetta P, Kamangar F, Amiriani T, Norouzi A, Dawsey S, Malekzadeh R, Abnet CC. One-carbon metabolism biomarkers and upper gastrointestinal cancer in the Golestan Cohort Study. Int J Cancer. 2024 Dec 01; 155(11):1944-1957.
-
Xia WF, Zheng XL, Liu WY, Huang YT, Wen CJ, Zhou HH, Wu QC, Wu LX. Romidepsin exhibits anti-esophageal squamous cell carcinoma activity through the DDIT4-mTORC1 pathway. Cancer Gene Ther. 2024 May; 31(5):778-789.
-
Etemadi A, Poustchi H, Chang CM, Calafat AM, Blount BC, Bhandari D, Wang L, Roshandel G, Alexandridis A, Botelho JC, Xia B, Wang Y, Sosnoff CS, Feng J, Nalini M, Khoshnia M, Pourshams A, Sotoudeh M, Gail MH, Dawsey SM, Kamangar F, Boffetta P, Brennan P, Abnet CC, Malekzadeh R, Freedman ND. Exposure to polycyclic aromatic hydrocarbons, volatile organic compounds, and tobacco-specific nitrosamines and incidence of esophageal cancer. J Natl Cancer Inst. 2024 03 07; 116(3):379-388.
-
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, Widmann K, Kapoor VN, Vexler V, Keegan P, Yao S, LaVallee T, Khare SD. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024 Feb 24; 73(3):60.